What is the role of pulmonary function tests in Chronic Obstructive Pulmonary Disease (COPD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Pulmonary function tests, particularly spirometry, are crucial for diagnosing and managing Chronic Obstructive Pulmonary Disease (COPD), as they provide objective measurements of airflow obstruction and disease severity, guiding treatment decisions and monitoring progression 1. The most important pulmonary function test for COPD is spirometry, which measures FEV1 (forced expiratory volume in one second) and FVC (forced vital capacity).

  • A post-bronchodilator FEV1/FVC ratio less than 0.7 confirms airflow obstruction characteristic of COPD, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report 1.
  • The severity of COPD is classified based on FEV1 percentage of predicted value, with categories including mild, moderate, severe, and very severe. Additional pulmonary function tests, such as lung volume measurements and diffusion capacity (DLCO), can provide further information on hyperinflation, air trapping, and gas exchange impairment.
  • These tests are essential for determining the appropriate treatment, including bronchodilators, inhaled corticosteroids, and oxygen therapy, and for identifying candidates for interventions like lung volume reduction procedures 1. The use of pre- and post-bronchodilator spirometry is recommended for the diagnosis of COPD, with the post-bronchodilator FEV1/FVC ratio being the most important measurement 1. It is also important to consider the potential variability in FEV1/FVC results due to variable expiratory times influencing the FVC values obtained, and the use of forced expiratory volume in 6 s (FEV6) rather than FVC has been suggested as a means of overcoming this variability 1.
  • However, the GOLD 2025 report recommends using the FEV1/FVC ratio to identify airflow obstruction, and if there is a strong clinical suspicion of COPD and the FEV1/FVC ratio is normal, further follow-up and investigations, including assessment of the FEV1/SVC ratio, are recommended 1.

From the FDA Drug Label

The 8 trials enrolled patients with nonreversible obstructive lung disease (FEV 1 /FVC ≤70% and ≤12% or 200 mL improvement in FEV 1 in response to 4 puffs of albuterol/salbutamol) COPD exacerbations and lung function (FEV 1) were co-primary efficacy outcome measures in the four 1-year trials.

The role of pulmonary function tests in Chronic Obstructive Pulmonary Disease (COPD) is to measure lung function, specifically FEV1 (Forced Expiratory Volume in 1 second), which is used as a primary efficacy outcome measure to assess the severity of COPD and the effectiveness of treatment 2.

  • Pulmonary function tests are used to diagnose and monitor COPD.
  • FEV1/FVC ratio is used to confirm nonreversible obstructive lung disease.

From the Research

Role of Pulmonary Function Tests in COPD

Pulmonary function tests play a crucial role in the diagnosis and management of Chronic Obstructive Pulmonary Disease (COPD). The key tests used include:

  • Spirometry to assess airway obstruction 3, 4, 5, 6
  • Full-body plethysmography to assess lung hyperinflation and pulmonary emphysema 3
  • Diffusion capacity to assess gas exchange 3, 6
  • Exercise testing to assess exercise tolerance and phenotyping of COPD 6

Diagnosis and Staging of COPD

Pulmonary function testing is essential for the diagnosis and staging of COPD severity. The current diagnostic criterion for airflow obstruction is a ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) < 70% 4, 5. However, this definition can lead to false-negative determinations in younger patients and false-positive determinations in the elderly 5.

Treatment Guidance

Pulmonary function testing is used to guide treatment decisions, including:

  • Pharmaceutical treatment for patients with co-existing airway obstruction 3
  • Non-pharmaceutical treatment, such as endoscopic or surgical lung volume reduction, long-term oxygen therapy, long-term non-invasive ventilation, and lung transplantation 3
  • Rehabilitation programs and guideline adherence 4

Limitations of Pulmonary Function Tests

While pulmonary function tests are essential for the diagnosis and management of COPD, they have limitations. For example:

  • Spirometry may not detect small airways disease or COPD symptoms in patients with normal lung function 6, 7
  • Screening spirometry is not recommended for asymptomatic individuals or those without risk factors for COPD 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[COPD - Importance of Lung Function Testing for Diagnosis and Treatment].

Deutsche medizinische Wochenschrift (1946), 2018

Research

Assessment of pulmonary function in COPD.

Seminars in respiratory and critical care medicine, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.